PIDB
MCID: PCK003
MIFTS: 64

Pick Disease of Brain (PIDB)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pick Disease of Brain

MalaCards integrated aliases for Pick Disease of Brain:

Name: Pick Disease of Brain 57 12
Pick's Disease 12 53 54 29 6 15
Pick Disease of the Brain 53 75 44 73
Pick Disease 57 12 76 13
Dementia with Lobar Atrophy and Neuronal Cytoplasmic Inclusions 57 53 75
Lobar Atrophy of Brain 57 12 75
Dementia in Pick's Disease 12
Lobar Atrophy of the Brain 53
Pick's Disease of Brain 40
Picks Disease 55
Pidb 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant
isolated cases

Miscellaneous:
phenotypic overlap with frontotemporal dementia


HPO:

32
pick disease of brain:
Inheritance autosomal dominant inheritance sporadic


Classifications:



Summaries for Pick Disease of Brain

NINDS : 54 Frontotemporal dementia (FTD) describes a clinical syndrome associated with shrinking of the frontal and temporal anterior lobes of the brain. Originally known as Pick’s disease, the name and classification of FTD has been a topic of discussion for over a century.  The current designation of the syndrome groups together Pick’s disease, primary progressive aphasia, and semantic dementia as FTD.  Some doctors propose adding corticobasal degeneration and progressive supranuclear palsy to FTD and calling the group Pick Complex.  These designations will continue to be debated.  As it is defined today, the symptoms of FTD fall into two clinical patterns that involve either (1) changes in behavior, or (2) problems with language.  The first type features behavior that can be either impulsive (disinhibited) or bored and listless (apathetic) and includes inappropriate social behavior; lack of social tact; lack of empathy; distractability; loss of insight into the behaviors of oneself and others; an increased interest in sex; changes in food preferences; agitation or, conversely, blunted emotions; neglect of personal hygiene; repetitive or compulsive behavior, and decreased energy and motivation.  The second type primarily features symptoms of language disturbance, including difficulty making or understanding speech, often in conjunction with the behavioral type’s symptoms.  Spatial skills and memory remain intact.  There is a strong genetic component to the disease; FTD often runs in families.

MalaCards based summary : Pick Disease of Brain, also known as pick's disease, is related to supranuclear palsy, progressive, 1 and frontotemporal dementia, and has symptoms including myoclonus and personality changes. An important gene associated with Pick Disease of Brain is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Neuroscience and Microglia Activation During Neuroinflammation: Overview. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone, and related phenotypes are stereotypy and irritability

NIH Rare Diseases : 53 Pick�??s disease is a neurological condition characterized by a slowly progressive deterioration of behavior, personality, or language. People with Pick's disease have abnormal substances (called Pick bodies) inside nerve cells in the damaged areas of the brain. Pick bodies contain an abnormal form of a protein called tau. This protein is found in all nerve cells, but people with Pick's disease have an abnormal amount or type of this protein. Symptoms often present sometime in the 50s, though it can occur as early as age 20 or as late as age 80. The course of the disease varies from person to person. The underlying cause of Pick's disease is unknown. In some cases, the disease runs in families. While there is no treatment to slow the progression of the disease, medications can be used to treat individual symptoms.

OMIM : 57 Pick disease refers to the neuropathologic finding of 'Pick bodies,' which are argyrophilic, intraneuronal inclusions, and 'Pick cells,' which are enlarged neurons. The clinical correlates of Pick disease of brain include those of frontotemporal dementia, which encompass the behavioral variant of FTD, semantic dementia, and progressive nonfluent aphasia (summary by Piguet et al., 2011). Kertesz (2003) suggested the term 'Pick complex' to represent the overlapping syndromes of FTD, primary progressive aphasia (PPA), corticobasal degeneration (CBD), progressive supranuclear palsy (601104), and FTD with motor neuron disease. He noted that frontotemporal dementia may also be referred to as 'clinical Pick disease,' and that the term 'Pick disease' should be restricted to the pathologic finding of Pick bodies. (172700)

UniProtKB/Swiss-Prot : 75 Pick disease of the brain: A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

Wikipedia : 76 Pick''s disease is a specific pathology that is one of the causes of frontotemporal lobar degeneration.... more...

Related Diseases for Pick Disease of Brain

Diseases related to Pick Disease of Brain via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 supranuclear palsy, progressive, 1 31.4 TARDBP SNCA RPS27A PSEN1 MAPT GRN
2 frontotemporal dementia 30.6 TARDBP SQSTM1 SNCA RPS27A PSEN1 MAPT
3 corticobasal degeneration 30.1 TARDBP RPS27A MAPT CRYAB
4 kluver-bucy syndrome 29.8 PSEN1 MAPT APP
5 multiple system atrophy 1 29.7 SQSTM1 SNCA RPS27A MAPT
6 amyloidosis 29.6 SNCA PSEN1 APP APOE
7 tremor 29.5 SNCA MAPT FUS
8 alzheimer disease 29.1 TARDBP SQSTM1 SNCA PSEN1 MAPT GRN
9 dementia 28.8 TARDBP SQSTM1 SNCA PSEN1 MAPT GRN
10 niemann-pick disease, type c1 12.8
11 niemann-pick disease, type a 12.8
12 niemann-pick disease, type b 12.8
13 niemann-pick disease 12.7
14 niemann-pick disease, type c2 12.7
15 niemann-pick disease type c, juvenile neurologic onset 12.1
16 niemann-pick disease type c, severe perinatal form 12.1
17 niemann-pick disease type c, late infantile neurologic onset 12.1
18 niemann-pick disease type c, severe early infantile neurologic onset 12.1
19 niemann-pick disease type c, adult neurologic onset 12.1
20 acid sphingomyelinase deficiency 11.6
21 sea-blue histiocyte disease 11.3
22 sphingolipidosis 11.3
23 simultanagnosia 10.3 MAPT APOE
24 primary lateral sclerosis, adult, 1 10.2 SNCA MAPT
25 posterior cortical atrophy 10.2 MAPT APOE
26 parkinson disease 3, autosomal dominant 10.2 SNCA MAPT
27 early-onset, autosomal dominant alzheimer disease 10.2 PSEN1 APP
28 alzheimer disease 4 10.2 PSEN1 APOE
29 arteriolosclerosis 10.2 TARDBP APOE
30 alzheimer's disease 1 10.2 APP APOE
31 postencephalitic parkinson disease 10.2 TARDBP SNCA MAPT
32 neuronal intranuclear inclusion disease 10.2 SNCA RPS27A MAPT
33 head injury 10.2 CHAT APOE
34 alexia 10.2 TARDBP PSEN1 APOE
35 gaucher's disease 10.2
36 histiocytosis 10.2
37 alzheimer disease mitochondrial 10.2 MAPT APP
38 synucleinopathy 10.1 SNCA MAPT APP
39 rem sleep behavior disorder 10.1 SNCA RPS27A
40 marcus gunn phenomenon 10.1 TUBB3 CHAT
41 lipoprotein glomerulopathy 10.1 CLU APOE
42 senile plaque formation 10.1 CHAT APP APOE
43 urethral benign neoplasm 10.1 CHGA APP
44 prosopagnosia 10.1 PSEN1 GRN
45 infantile liver failure syndrome 1 10.1
46 cerebrovascular disease 10.1 MAPT APP APOE
47 olfactory nerve neoplasm 10.1 TUBB3 CHGA
48 familial idiopathic basal ganglia calcification 10.1 PSEN1 MAPT APP APOE
49 kohlschutter-tonz syndrome 10.1 PSEN1 MAPT APP APOE
50 pineocytoma 10.1 TUBB3 CHGA

Graphical network of the top 20 diseases related to Pick Disease of Brain:



Diseases related to Pick Disease of Brain

Symptoms & Phenotypes for Pick Disease of Brain

Symptoms via clinical synopsis from OMIM:

57
Neurologic Behavioral Psychiatric Manifestations:
irritability
disinhibition
apathy
personality changes
echolalia
more
Neurologic Central Nervous System:
language impairment
frontotemporal dementia
neuronal loss
frontotemporal lobar atrophy with 'knife-edge' distinction
atrophy may be more severe in the left hemisphere
more

Clinical features from OMIM:

172700

Human phenotypes related to Pick Disease of Brain:

32 (show all 16)
# Description HPO Frequency HPO Source Accession
1 stereotypy 32 HP:0000733
2 irritability 32 HP:0000737
3 polyphagia 32 HP:0002591
4 language impairment 32 HP:0002463
5 disinhibition 32 HP:0000734
6 apathy 32 HP:0000741
7 personality changes 32 HP:0000751
8 frontotemporal dementia 32 HP:0002145
9 neuronal loss in central nervous system 32 HP:0002529
10 gliosis 32 HP:0002171
11 echolalia 32 HP:0010529
12 perseveration 32 HP:0030223
13 hyperorality 32 HP:0000710
14 emotional blunting 32 HP:0030213
15 primitive reflex 32 HP:0002476
16 inappropriate laughter 32 HP:0000748

UMLS symptoms related to Pick Disease of Brain:


myoclonus, personality changes

MGI Mouse Phenotypes related to Pick Disease of Brain:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 APOE APP CHAT CLU CRYAB GRN
2 cellular MP:0005384 10.24 APOE APP CD59 CRYAB GRN MAPT
3 homeostasis/metabolism MP:0005376 10.23 APOE APP CD59 CHAT CHGA CLU
4 growth/size/body region MP:0005378 10.18 APOE APP CHAT CHGA GRN MAPT
5 mortality/aging MP:0010768 10.18 APOE APP CD59 CHAT CHGA GRN
6 nervous system MP:0003631 10.13 APOE APP CHAT CHGA CLU GRN
7 immune system MP:0005387 10.09 APOE APP CLU GRN MAPT PSEN1
8 muscle MP:0005369 10.02 APOE APP CHAT CHGA CLU CRYAB
9 no phenotypic analysis MP:0003012 9.8 APOE APP CHGA GRN MAPT SNCA
10 renal/urinary system MP:0005367 9.7 APOE CD59 CHGA CLU MAPT PSEN1
11 reproductive system MP:0005389 9.56 APOE APP CD59 CHAT CHGA GRN
12 vision/eye MP:0005391 9.17 APOE CHAT CRYAB GRN MAPT PSEN1

Drugs & Therapeutics for Pick Disease of Brain

Drugs for Pick Disease of Brain (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
3
Citalopram Approved Phase 4 59729-33-8 2771
4
Iodine Approved, Investigational Phase 4 7553-56-2 807
5
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
7 Antiparkinson Agents Phase 4,Phase 3,Phase 2
8 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1,Not Applicable
10 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
11 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
12 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
13 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
14 Neurotransmitter Uptake Inhibitors Phase 4
15 Antidepressive Agents, Second-Generation Phase 4
16 Antidepressive Agents Phase 4,Phase 2,Phase 1
17 Serotonin Uptake Inhibitors Phase 4
18 Serotonin Agents Phase 4,Phase 3
19 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Anti-Inflammatory Agents Phase 4,Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
23 Analgesics, Non-Narcotic Phase 4,Phase 1
24 Analgesics Phase 4,Phase 1
25 Calamus Phase 4
26 cadexomer iodine Phase 4
27
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
28 tannic acid Approved Phase 3
29
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
30
Methylene blue Approved, Investigational Phase 3 61-73-4
31
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
32
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
33
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 6055-19-2, 50-18-0 2907
34
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
36
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
37
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
38
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
39
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
40
Iron Approved Phase 2, Phase 3 7439-89-6 23925
41
1-Deoxynojirimycin Experimental, Investigational Phase 3,Phase 2 19130-96-2 1374
42
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
43 Cardiac Glycosides Phase 3,Phase 2,Phase 1
44 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
45 Glycoside Hydrolase Inhibitors Phase 3,Phase 2,Phase 1
46 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
47 Anti-HIV Agents Phase 3,Phase 2,Phase 1
48 Prednisolone acetate Phase 2, Phase 3
49 Immunosuppressive Agents Phase 2, Phase 3
50 Methylprednisolone acetate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 175)
# Name Status NCT ID Phase Drugs
1 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
2 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
3 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
4 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
5 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
6 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
7 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
8 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
9 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
10 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
11 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
12 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
13 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
14 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
15 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
16 SurVival of Lysosomal Acid Lipase Deficiency (LAL-D) Infants Treated With SebelipAse aLfa Active, not recruiting NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)
17 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
18 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
19 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
20 Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102 Terminated NCT01473875 Phase 2, Phase 3 SBC-102
21 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
22 Effects of Tolcapone on Frontotemporal Dementia Unknown status NCT00604591 Phase 2 Tolcapone;Placebo
23 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Unknown status NCT02676843 Phase 2 18F-AV-1451
24 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
25 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
26 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
27 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Completed NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
28 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
29 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
30 Double Blind Trial of DC Polarization in FTD Completed NCT00117858 Phase 2
31 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Completed NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
32 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
33 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
34 Intranasal Oxytocin for Frontotemporal Dementia Recruiting NCT03260920 Phase 2 Syntocinon
35 Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia Recruiting NCT02862210 Phase 2 Lithium Carbonate;Placebo
36 Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Recruiting NCT03471143 Phase 1, Phase 2 2-Hydroxypropyl-Beta-Cyclodextrin
37 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
38 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
39 F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis Active, not recruiting NCT02414230 Phase 2 Drug: F 18 T807
40 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
41 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
42 Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency Active, not recruiting NCT02193867 Phase 2 sebelipase alfa
43 F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) Enrolling by invitation NCT02414282 Phase 2 F 18 T807
44 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
45 N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) Not yet recruiting NCT03759639 Phase 2 IB1001
46 Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease Not yet recruiting NCT03687476 Phase 2 VTS-270
47 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
48 F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) Withdrawn NCT02707978 Phase 2 F 18 T807
49 Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia Unknown status NCT00674960 Phase 1
50 Far Infrared Radiation Treatment of Dementia and Other Mental Illness Unknown status NCT00574054 Phase 1

Search NIH Clinical Center for Pick Disease of Brain

Cochrane evidence based reviews: pick disease of the brain

Genetic Tests for Pick Disease of Brain

Genetic tests related to Pick Disease of Brain:

# Genetic test Affiliating Genes
1 Pick's Disease 29 MAPT PSEN1

Anatomical Context for Pick Disease of Brain

MalaCards organs/tissues related to Pick Disease of Brain:

41
Brain, Liver, Bone, Cortex, Lung, Spleen, Bone Marrow

Publications for Pick Disease of Brain

Articles related to Pick Disease of Brain:

(show top 50) (show all 291)
# Title Authors Year
1
Structures of filaments from Pick's disease reveal a novel tau protein fold. ( 30158706 )
2018
2
Pick's disease with neuronal four-repeat tau accumulation in the basal ganglia, brain stem nuclei and cerebellum. ( 28691164 )
2017
3
Semi-Automated Digital Image Analysis of Pick's Disease and TDP-43 Proteinopathy. ( 26538548 )
2016
4
A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick's Disease and Fronto-Temporal Tauopathies. ( 25803611 )
2015
5
Being Picky about Pick's disease: Considerations in the care of residents with frontotemporal dementia (FTD). ( 26244184 )
2015
6
Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. ( 26611895 )
2015
7
An autopsy case of incipient Pick's disease: immunohistochemical profile of early-stage Pick body formation. ( 24444359 )
2014
8
Primary progressive apraxia of speech (AOS) in a patient with Pick's disease with Pick bodies: a neuropsychological and anatomical study and review of literatures. ( 22500674 )
2013
9
Immunolocalization of an Amino-Terminal Fragment of Apolipoprotein E in the Pick's Disease Brain. ( 24312462 )
2013
10
'Limits and current knowledge of Pick's disease: its differential diagnosis'. A translation of the 1957 Delay, Brion, Escourolle article. ( 22554132 )
2013
11
Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. ( 22713404 )
2013
12
C1q, the classical complement pathway protein binds Hirano bodies in Pick's disease. ( 23512330 )
2013
13
Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. ( 22558197 )
2012
14
Pick's disease. ( 22411252 )
2012
15
Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease. ( 21881831 )
2011
16
Neuronal and glial tau pathology in early frontotemporal lobar degeneration-tau, Pick's disease subtype. ( 20022024 )
2010
17
The journey through Pick's Disease with a loved one: a personal account. ( 20487487 )
2010
18
Frontotemporal dementia, Pick's disease. ( 20420119 )
2010
19
Clinicopathological characterization of Pick's disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions. ( 19194716 )
2009
20
Caspase-cleaved TAR DNA-binding protein-43 in Pick's disease. ( 20411029 )
2009
21
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. ( 19693433 )
2009
22
Up-regulation of adenosine A1 receptors in frontal cortex from Pick's disease cases. ( 18052973 )
2007
23
Pick's disease with Pick bodies: an unusual autopsy case showing degeneration of the pontine nucleus, dentate nucleus, Clarke's column, and lower motor neuron. ( 17319287 )
2007
24
Expression of transcription factors c-Fos, c-Jun, CREB-1 and ATF-2, and caspase-3 in relation with abnormal tau deposits in Pick's disease. ( 16496165 )
2006
25
Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick's disease. ( 16987245 )
2006
26
The corpus callosum in Pick's disease, Alzheimer's disease, and amyotrophic lateral sclerosis: gliosis implies possible clinical consequence. ( 16526588 )
2006
27
Pick's disease. ( 17076146 )
2006
28
An individualized approach to treatment for alzheimer's disease, pick's disease, and other dementias. ( 17062555 )
2006
29
Pathological heterogeneity of the precentral gyrus in Pick's disease: a study of 16 autopsy cases. ( 16609852 )
2006
30
Adenosine A2A receptors are up-regulated in Pick's disease frontal cortex. ( 17107593 )
2006
31
Pick's disease with Pick bodies combined with progressive supranuclear palsy without tuft-shaped astrocytes: a clinical, neuroradiologic and pathological study of an autopsied case. ( 16771179 )
2006
32
Progress in clinical neurosciences: Frontotemporal dementia-pick's disease. ( 16736722 )
2006
33
Notch-1 immunoexpression is increased in Alzheimer's and Pick's disease. ( 16473372 )
2006
34
Abnormal alpha-synuclein solubility, aggregation and nitration in the frontal cortex in Pick's disease. ( 16516382 )
2006
35
BetaII-tubulin and phospho-tau aggregates in Alzheimer's disease and Pick's disease. ( 16006664 )
2005
36
Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease. ( 15661359 )
2005
37
Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. ( 16014652 )
2005
38
Presenile dementia mimicking Pick's disease: an autopsy case of localized amygdala degeneration with character change and emotional disorder. ( 16193841 )
2005
39
Ubiquitin and ubiquitin-related proteins in the brains of patients with atypical Pick's disease without Pick bodies and dementia with motor neuron disease. ( 15641590 )
2004
40
Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. ( 14991385 )
2004
41
Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. ( 14689204 )
2004
42
Pick's disease pathology of a missense mutation of S305N of frontotemporal dementia and parkinsonism linked to chromosome 17: another phenotype of S305N. ( 15178939 )
2004
43
Frontotemporal dementia/Pick's disease. ( 15210543 )
2004
44
Genetic aspects of Alzheimer's disease, Pick's disease, and other dementias. ( 15359559 )
2004
45
Synaptophysin immunoreactivity in Pick's disease: comparison with Alzheimer's disease and dementia with Lewy bodies. ( 15633942 )
2004
46
A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. ( 15122701 )
2004
47
Ubiquitin and ubiquitin-related proteins in neurons and dendrites of brains of atypical Pick's disease without Pick bodies. ( 15068171 )
2004
48
Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. ( 12615642 )
2003
49
Alterations of muscarinic acetylcholine receptors in atypical Pick's disease without Pick bodies. ( 12810794 )
2003
50
Pick's disease. ( 12531941 )
2003

Variations for Pick Disease of Brain

UniProtKB/Swiss-Prot genetic disease variations for Pick Disease of Brain:

75
# Symbol AA change Variation ID SNP ID
1 MAPT p.Lys574Thr VAR_010344 rs63750129
2 MAPT p.Gly706Arg VAR_010352 rs63750512
3 MAPT p.Ser637Phe VAR_019665 rs63750635
4 MAPT p.Lys686Ile VAR_019668 rs63751264

ClinVar genetic disease variations for Pick Disease of Brain:

6 (show all 48)
# Gene Variation Type Significance SNP ID Assembly Location
1 MAPT NM_005910.5(MAPT): c.1165G> A (p.Gly389Arg) single nucleotide variant Likely pathogenic rs63750512 GRCh37 Chromosome 17, 44101376: 44101376
2 MAPT NM_005910.5(MAPT): c.1165G> A (p.Gly389Arg) single nucleotide variant Likely pathogenic rs63750512 GRCh38 Chromosome 17, 46024010: 46024010
3 MAPT NM_016835.4(MAPT): c.1721A> C (p.Lys574Thr) single nucleotide variant Pathogenic rs63750129 GRCh37 Chromosome 17, 44073978: 44073978
4 MAPT NM_016835.4(MAPT): c.1721A> C (p.Lys574Thr) single nucleotide variant Pathogenic rs63750129 GRCh38 Chromosome 17, 45996612: 45996612
5 MAPT NM_016835.4(MAPT): c.2057A> T (p.Lys686Ile) single nucleotide variant Pathogenic rs63751264 GRCh37 Chromosome 17, 44096092: 44096092
6 MAPT NM_016835.4(MAPT): c.2057A> T (p.Lys686Ile) single nucleotide variant Pathogenic rs63751264 GRCh38 Chromosome 17, 46018726: 46018726
7 MAPT NM_016835.4(MAPT): c.1910C> T (p.Ser637Phe) single nucleotide variant Pathogenic rs63750635 GRCh37 Chromosome 17, 44091652: 44091652
8 MAPT NM_016835.4(MAPT): c.1910C> T (p.Ser637Phe) single nucleotide variant Pathogenic rs63750635 GRCh38 Chromosome 17, 46014286: 46014286
9 PSEN1 NM_000021.3(PSEN1): c.488A> G (p.His163Arg) single nucleotide variant Pathogenic rs63750590 GRCh37 Chromosome 14, 73653568: 73653568
10 PSEN1 NM_000021.3(PSEN1): c.488A> G (p.His163Arg) single nucleotide variant Pathogenic rs63750590 GRCh38 Chromosome 14, 73186860: 73186860
11 PSEN1 NM_000021.3(PSEN1): c.737C> A (p.Ala246Glu) single nucleotide variant Pathogenic rs63750526 GRCh37 Chromosome 14, 73659540: 73659540
12 PSEN1 NM_000021.3(PSEN1): c.737C> A (p.Ala246Glu) single nucleotide variant Pathogenic rs63750526 GRCh38 Chromosome 14, 73192832: 73192832
13 PSEN1 NM_000021.3(PSEN1): c.1229G> A (p.Cys410Tyr) single nucleotide variant Pathogenic rs661 GRCh37 Chromosome 14, 73683933: 73683933
14 PSEN1 NM_000021.3(PSEN1): c.1229G> A (p.Cys410Tyr) single nucleotide variant Pathogenic rs661 GRCh38 Chromosome 14, 73217225: 73217225
15 PSEN1 NM_000021.3(PSEN1): c.839A> C (p.Glu280Ala) single nucleotide variant Pathogenic rs63750231 GRCh37 Chromosome 14, 73664808: 73664808
16 PSEN1 NM_000021.3(PSEN1): c.839A> C (p.Glu280Ala) single nucleotide variant Pathogenic rs63750231 GRCh38 Chromosome 14, 73198100: 73198100
17 PSEN1 NM_000021.3(PSEN1): c.617G> C (p.Gly206Ala) single nucleotide variant Pathogenic rs63750082 GRCh37 Chromosome 14, 73659420: 73659420
18 PSEN1 NM_000021.3(PSEN1): c.617G> C (p.Gly206Ala) single nucleotide variant Pathogenic rs63750082 GRCh38 Chromosome 14, 73192712: 73192712
19 PSEN1 NM_000021.3(PSEN1): c.548G> T (p.Gly183Val) single nucleotide variant Pathogenic rs63751068 GRCh37 Chromosome 14, 73653628: 73653628
20 PSEN1 NM_000021.3(PSEN1): c.548G> T (p.Gly183Val) single nucleotide variant Pathogenic rs63751068 GRCh38 Chromosome 14, 73186920: 73186920
21 PSEN1 NM_000021.3(PSEN1): c.1292C> A (p.Ala431Glu) single nucleotide variant Pathogenic rs63750083 GRCh37 Chromosome 14, 73685885: 73685885
22 PSEN1 NM_000021.3(PSEN1): c.1292C> A (p.Ala431Glu) single nucleotide variant Pathogenic rs63750083 GRCh38 Chromosome 14, 73219177: 73219177
23 PSEN1 NM_000021.3(PSEN1): c.236C> T (p.Ala79Val) single nucleotide variant Pathogenic rs63749824 GRCh37 Chromosome 14, 73637653: 73637653
24 PSEN1 NM_000021.3(PSEN1): c.236C> T (p.Ala79Val) single nucleotide variant Pathogenic rs63749824 GRCh38 Chromosome 14, 73170945: 73170945
25 PSEN1 NM_000021.3(PSEN1): c.806G> A (p.Arg269His) single nucleotide variant Pathogenic rs63750900 GRCh37 Chromosome 14, 73664775: 73664775
26 PSEN1 NM_000021.3(PSEN1): c.806G> A (p.Arg269His) single nucleotide variant Pathogenic rs63750900 GRCh38 Chromosome 14, 73198067: 73198067
27 PSEN1 NM_000021.3(PSEN1): c.104G> A (p.Arg35Gln) single nucleotide variant Uncertain significance rs63750592 GRCh37 Chromosome 14, 73637521: 73637521
28 PSEN1 NM_000021.3(PSEN1): c.104G> A (p.Arg35Gln) single nucleotide variant Uncertain significance rs63750592 GRCh38 Chromosome 14, 73170813: 73170813
29 PSEN1 NM_000021.3(PSEN1): c.344A> G (p.Tyr115Cys) single nucleotide variant Pathogenic rs63750450 GRCh37 Chromosome 14, 73640279: 73640279
30 PSEN1 NM_000021.3(PSEN1): c.344A> G (p.Tyr115Cys) single nucleotide variant Pathogenic rs63750450 GRCh38 Chromosome 14, 73173571: 73173571
31 PSEN1 NM_000021.3(PSEN1): c.532T> C (p.Ser178Pro) single nucleotide variant Uncertain significance rs63750155 GRCh37 Chromosome 14, 73653612: 73653612
32 PSEN1 NM_000021.3(PSEN1): c.532T> C (p.Ser178Pro) single nucleotide variant Uncertain significance rs63750155 GRCh38 Chromosome 14, 73186904: 73186904
33 PSEN1 NM_000021.3(PSEN1): c.626G> T (p.Gly209Val) single nucleotide variant Pathogenic rs63750053 GRCh37 Chromosome 14, 73659429: 73659429
34 PSEN1 NM_000021.3(PSEN1): c.626G> T (p.Gly209Val) single nucleotide variant Pathogenic rs63750053 GRCh38 Chromosome 14, 73192721: 73192721
35 PSEN1 NM_000021.3(PSEN1): c.953A> G (p.Glu318Gly) single nucleotide variant Benign/Likely benign rs17125721 GRCh37 Chromosome 14, 73673178: 73673178
36 PSEN1 NM_000021.3(PSEN1): c.953A> G (p.Glu318Gly) single nucleotide variant Benign/Likely benign rs17125721 GRCh38 Chromosome 14, 73206470: 73206470
37 MAPT NM_001123066.3(MAPT): c.623delG (p.Gly208Alafs) deletion Uncertain significance rs1085307079 GRCh38 Chromosome 17, 45983427: 45983427
38 MAPT NM_001123066.3(MAPT): c.623delG (p.Gly208Alafs) deletion Uncertain significance rs1085307079 GRCh37 Chromosome 17, 44060793: 44060793
39 PSEN1 NM_000021.3(PSEN1): c.-296C> T single nucleotide variant Benign/Likely benign rs1800839 GRCh37 Chromosome 14, 73603131: 73603131
40 PSEN1 NM_000021.3(PSEN1): c.-296C> T single nucleotide variant Benign/Likely benign rs1800839 GRCh38 Chromosome 14, 73136423: 73136423
41 PSEN1 NM_000021.3(PSEN1): c.-528C> G single nucleotide variant Benign rs34086577 GRCh38 Chromosome 14, 73136191: 73136191
42 PSEN1 NM_000021.3(PSEN1): c.-528C> G single nucleotide variant Benign rs34086577 GRCh37 Chromosome 14, 73602899: 73602899
43 MAPT NM_016841.4(MAPT): c.47G> T (p.Gly16Val) single nucleotide variant Uncertain significance rs755131800 GRCh37 Chromosome 17, 44039750: 44039750
44 MAPT NM_016841.4(MAPT): c.47G> T (p.Gly16Val) single nucleotide variant Uncertain significance rs755131800 GRCh38 Chromosome 17, 45962384: 45962384
45 PSEN1 NM_000021.3(PSEN1): c.869-2A> T single nucleotide variant Pathogenic GRCh37 Chromosome 14, 73673092: 73673092
46 PSEN1 NM_000021.3(PSEN1): c.869-2A> T single nucleotide variant Pathogenic GRCh38 Chromosome 14, 73206384: 73206384
47 PSEN1 NM_000021.3(PSEN1): c.1148T> G (p.Leu383Trp) single nucleotide variant Uncertain significance GRCh37 Chromosome 14, 73683852: 73683852
48 PSEN1 NM_000021.3(PSEN1): c.1148T> G (p.Leu383Trp) single nucleotide variant Uncertain significance GRCh38 Chromosome 14, 73217144: 73217144

Expression for Pick Disease of Brain

Search GEO for disease gene expression data for Pick Disease of Brain.

Pathways for Pick Disease of Brain

GO Terms for Pick Disease of Brain

Cellular components related to Pick Disease of Brain according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.97 APP CHGA CLU PSEN1 SQSTM1
2 extracellular exosome GO:0070062 9.97 APOE APP CD59 CLU CRYAB GRN
3 perinuclear region of cytoplasm GO:0048471 9.96 APP CHGA CLU FUS SNCA
4 cell surface GO:0009986 9.93 APP CD59 CLU CRYAB PSEN1
5 dendrite GO:0030425 9.85 APOE FUS MAPT PSEN1 TUBB3
6 neuronal cell body GO:0043025 9.77 APOE FUS MAPT PSEN1 SNCA
7 rough endoplasmic reticulum GO:0005791 9.67 APP PSEN1 SNCA
8 inclusion body GO:0016234 9.58 SNCA SQSTM1
9 dendritic spine GO:0043197 9.56 APP CRYAB FUS MAPT
10 ciliary rootlet GO:0035253 9.52 APP PSEN1
11 main axon GO:0044304 9.48 APP MAPT
12 growth cone GO:0030426 9.46 APP MAPT PSEN1 SNCA
13 neurofibrillary tangle GO:0097418 9.4 CLU MAPT
14 axon GO:0030424 9.1 APP CRYAB MAPT PSEN1 SNCA TUBB3
15 chromaffin granule GO:0042583 8.96 CHGA CLU
16 nucleus GO:0005634 10.36 APOE CHAT CLU CRYAB FUS MAPT
17 cytoplasm GO:0005737 10.32 APOE APP CHAT CLU CRYAB FUS
18 extracellular region GO:0005576 10.15 APOE APP CD59 CHGA CLU GRN
19 Golgi apparatus GO:0005794 10.07 APOE APP CLU CRYAB PSEN1 SNCA
20 extracellular space GO:0005615 10.03 APOE APP CD59 CHGA CLU GRN

Biological processes related to Pick Disease of Brain according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.96 PSEN1 RPS27A SNCA SQSTM1
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 APP CLU RPS27A
3 negative regulation of neuron apoptotic process GO:0043524 9.86 APOE PSEN1 SNCA
4 response to oxidative stress GO:0006979 9.84 APOE APP PSEN1
5 negative regulation of gene expression GO:0010629 9.77 APOE APP CRYAB MAPT TARDBP
6 negative regulation of protein phosphorylation GO:0001933 9.75 PSEN1 SNCA TARDBP
7 negative regulation of neuron death GO:1901215 9.72 APOE CHGA SNCA
8 positive regulation of dendritic spine development GO:0060999 9.68 APOE PSEN1
9 regulation of protein binding GO:0043393 9.68 APP PSEN1
10 regulation of long-term neuronal synaptic plasticity GO:0048169 9.67 APP SNCA
11 response to lead ion GO:0010288 9.67 APP MAPT
12 regulation of neuron death GO:1901214 9.66 CLU SNCA
13 regulation of neuronal synaptic plasticity GO:0048168 9.66 APOE SNCA
14 positive regulation of long-term synaptic potentiation GO:1900273 9.65 APP SQSTM1
15 cellular protein metabolic process GO:0044267 9.65 APOE APP PSEN1 RPS27A SNCA
16 reverse cholesterol transport GO:0043691 9.64 APOE CLU
17 positive regulation of receptor recycling GO:0001921 9.64 PSEN1 SNCA
18 supramolecular fiber organization GO:0097435 9.63 MAPT SNCA
19 positive regulation of neuron death GO:1901216 9.63 CLU MAPT SNCA
20 amyloid precursor protein metabolic process GO:0042982 9.62 APOE PSEN1
21 virion assembly GO:0019068 9.62 APOE RPS27A
22 negative regulation of amyloid-beta formation GO:1902430 9.61 APOE CLU
23 negative regulation of long-term synaptic potentiation GO:1900272 9.61 APOE APP
24 neuron projection maintenance GO:1990535 9.6 APP PSEN1
25 positive regulation of amyloid-beta formation GO:1902004 9.59 APP CLU
26 amyloid fibril formation GO:1990000 9.58 APP MAPT
27 negative regulation of protein homooligomerization GO:0032463 9.57 CLU CRYAB
28 modulation of age-related behavioral decline GO:0090647 9.56 APP PSEN1
29 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.54 APP PSEN1
30 protein import GO:0017038 9.52 APOE CLU
31 negative regulation of amyloid fibril formation GO:1905907 9.51 CLU CRYAB
32 microglial cell activation GO:0001774 9.5 CLU MAPT SNCA
33 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.49 APP PSEN1
34 astrocyte activation involved in immune response GO:0002265 9.48 APP PSEN1
35 regulation of amyloid-beta clearance GO:1900221 9.43 APOE CLU
36 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.4 APP PSEN1
37 astrocyte activation GO:0048143 9.33 APP MAPT PSEN1
38 synapse organization GO:0050808 9.26 APP MAPT PSEN1 SNCA
39 positive regulation of amyloid fibril formation GO:1905908 8.92 APOE APP CLU PSEN1
40 apoptotic process GO:0006915 10.05 APP CLU PSEN1 SNCA SQSTM1
41 negative regulation of apoptotic process GO:0043066 10.03 CRYAB PSEN1 RPS27A SNCA SQSTM1

Molecular functions related to Pick Disease of Brain according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.71 APP MAPT SNCA SQSTM1
2 amyloid-beta binding GO:0001540 9.43 APOE CLU CRYAB
3 low-density lipoprotein particle receptor binding GO:0050750 9.37 APOE CLU
4 identical protein binding GO:0042802 9.23 APOE APP CRYAB FUS MAPT SNCA
5 lipoprotein particle binding GO:0071813 9.16 APOE MAPT
6 tau protein binding GO:0048156 9.13 APOE CLU SNCA
7 protein binding GO:0005515 10.2 APOE APP CD59 CLU CRYAB FUS

Sources for Pick Disease of Brain

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....